"The US Food and Drug Administration (FDA) has approved a riboflavin ophthalmic solution (Photrexa, Avedro) that treats a corneal disease called progressive keratoconus with corneal collagen crosslinking, the manufacturer announced today."...
DOSAGE AND ADMINISTRATION
The dose is 1-2 drops in each eye 4-6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium.
Patients should be advised that the effect of OPTICROM (cromolyn sodium ophthalmic solution) therapy is dependent upon its administration at regular intervals, as directed.
Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.
If required, corticosteroids may be used concomitantly with OPTICROM.
OPTICROM (cromolyn sodium ophthalmic solution, USP) 4% is supplied as 10 mL of solution in an opaque polyethylene eye drop bottle.
10 mL NDC 0023-6422-10
Store at Controlled Room Temperature 20-25°C (68-77°F). Protect from light - store in original carton. Keep tightly closed and out of the reach of children.
Allergan Inc., Irvine, CA 92612 U.S.A. Revised October 2000. FDA rev date: 4/12/2002This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/11/2008
Additional Opticrom Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.